Back to Pathway Library

Patient Initiated Journey

Rheumatoid Arthritis

Improve patient experience, letting them flag symptoms deterioration.

Currently, most patients with Rheumatoid Arthritis consult their physician every 3 to 6 months, following the European League Against Rheumatism (EULAR) guidelines. This method may be inefficient as, on one hand, 75% of patients are in a low disease activity state or remission and, on the other hand, flares often occur between outpatient clinic visits and can therefore still be missed and left untreated.

What does Hilly do?

  1. Contacts patients periodically to evaluate how symptoms are progressing;
  2. Gives patients the opportunity to alert healthcare professionals that a personal appointment is needed since symptoms get worse.

Key advantages

  • Ensure continuous monitoring of patients;
  • Empower patients on disease management;
  • Prevent rheumatoid arthritis decompensation;
  • Prioritize patients with worse disease control;
  • Optimize appointments time.

References

  • Barber CEH, Zell J, Yazdany J, et al. 2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2019;71(12):1531-1539. doi:10.1002/acr.24040
  • Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316-1322. doi:10.1136/annrheumdis-2013-204627
  • NICE guideline. Rheumatoid arthritis in adults: management. Last updated 12 October 2020. https://www.nice.org.uk/guidance/ng100
  • Seppen B, Wiegel J, Ter Wee MM, et al. Smartphone-Assisted Patient-Initiated Care Versus Usual Care in Patients With Rheumatoid Arthritis and Low Disease Activity: A Randomized Controlled Trial. Arthritis Rheumatol. 2022;10.1002/art.42292. doi:10.1002/art.42292
  • Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi:10.1136/annrheumdis-2019-216655

Move towards Patient-Centered care with UpHill

Talk to Sales